Safety and Effectiveness of the CCL Vario System for Corneal Collagen Cross-Linking in Eyes With Corneal Thinning Conditions
试验速览
- 阶段
- 早期 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 600
- 主要终点
- Occurrence of Adverse Events
研究概览
简要总结
Study is testing the efficacy of treating corneal thinning conditions with Vitamin B2 (Riboflavin) and the application on UV Light.
详细描述
Corneal thinning conditions, i.e. keratoconus or ectasia, weaken the cornea which then causes the front of the eye to bulge out. This results in distorted vision and could eventually result in the need for a cornea transplant. This study proposes to conclude that saturating the cornea with vitamin B2 (Riboflavin) and then applying 365nm wavelength of Ultra Violet Light will result in the various layers of corneal tissue linking together. This cross linking results in a stronger cornea which is designed to halt the progression of keratoconus or ectasia. This treatment is already being successfully used in Europe.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 12 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Presence of central or inferior corneal steepening
- •Axial topography consistent with keratoconus, post-surgical ectasia, or pellucid marginal degeneration
- •Presence of one or more findings associated with keratoconus or pellucid marginal degeneration, such as:
- •Fleischer ring
- •Vogt's striae
- •Decentered corneal apex
- •Munson's sign
- •Rizutti's sign
- •Apical corneal scarring consistent with Bowman's breaks
- •Scissoring of the retinoscopic reflex
- •Crab-claw appearance on topography
- •Steepest keratometry (Kmax) value > or = 47.20 D
- •I-S keratometry difference > 1.5 D on the Orbscan map
- •Posterior corneal elevation > 16 microns
- •Thinnest corneal point < 485 microns
- •Post LASIK/PRK stromal ablation depth < 300 microns or expected keratometry > 47.2 D, or post-PRK/SMILE in keratoconus suspect eyes
- •Bacterial or fungal corneal keratitis persistent and not responding despite > 2 weeks of standard antimicrobial therapy or with rapid progression of corneal thinning, with loss of > 25% corneal thickness
- •Contact Lens Wearers Only:
- •Removal of contact lenses for the required period of time prior to the screening refraction:
- •Contact Lens Type Minimum Discontinuation Time Soft 1 Week Soft Extended Wear 2 Weeks Soft Toric 3 Weeks Rigid Gas Permeable 2 Weeks per decade of wear
- •Signed written informed consent
- •Willingness and ability to comply with schedule for follow-up visits
排除标准
- •Eyes classified as either normal or atypical normal on the severity grading scheme
- •Corneal pachymetry at the screening exam that is < 400 microns at the thinnest point in the eye(s) to be treated when the transepithelial (isotonic) riboflavin solution alone will be used or < 300 microns when the hypotonic riboflavin will be used.
- •Previous ocular condition (other than refractive error) in the eye(s) to be treated that may predispose the eye for future complications, for example:
- •History of or active corneal disease (e.g., herpes simplex, herpes zoster keratitis, recurrent erosion syndrome, acanthamoeba, etc.)
- •Clinically significant corneal scarring in the CXL treatment zone that is not related to keratoconus or, in the investigator's opinion, will interfere with the cross linking procedure
- •Pregnancy (including plan to become pregnant) or lactation during the course of the study
- •A known sensitivity to study medications
- •Patients with nystagmus or any other condition that would prevent a steady gaze during the CXL treatment or other diagnostic tests
- •Patients with a current condition that, in the physician's opinion, would interfere with or prolong epithelial healing
研究组 & 干预措施
Cross linking treatment for corneal thinning
Cornea will be saturated with Vitamin B2 (Riboflavin) and then treated with 365 nm wavelength ultra violet light.
干预措施: Riboflavin (Drug)
结局指标
主要结局
Occurrence of Adverse Events
时间窗: Through study completion, an average of 1 year
Surgeon notes any occurrence of adverse events related to the treatment
Change in Best Corrected Visual Acuity
时间窗: Baseline and 1 year
Use a standard eye chart to determine changes in the subject's best Visual Acuity (with glasses or contact) performed by research staff
Change in Uncorrected Visual Acuity
时间窗: Baseline and 1 year
Use a standard eye chart to determine changes in the subject's best Visual Acuity (without glasses or contact) performed by clinic technician
次要结局
未报告次要终点
研究者
Kent Wellish MD
President and Medical Director
Wellish Vision Institute